메뉴 건너뛰기
The Lancet Neurology
Volumn 13, Issue 11, 2014, Pages 1065-1067
CGRP as a new target in prevention and treatment of migraine
Author keywords

[No Author keywords available]
Indexed keywords

ANTIBODY; CALCITONIN GENE RELATED PEPTIDE; CALCITONIN GENE RELATED PEPTIDE ANTIBODY; CALCITONIN GENE RELATED PEPTIDE RECEPTOR; CALCITONIN GENE RELATED PEPTIDE RECEPTOR ANTAGONIST; IMMUNOGLOBULIN G1 ANTIBODY; UNCLASSIFIED DRUG; MONOCLONAL ANTIBODY;
EID: 84907970699     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(14)70228-5     Document Type: Note
Times cited : (25)
References (11)
  • 1
    • 2142803810 scopus 로고    scopus 로고
    • Evidence of the involvement of CGRP in migraine and cluster headache: a physiological perspective
    • Landes Bioscience, Georgetown, Texas, D. Poyner, I. Marshall, S. Brain (Eds.)
    • Goadsby PJ Evidence of the involvement of CGRP in migraine and cluster headache: a physiological perspective. The CGRP family: calcitonin gene-related peptide (CGRP), amylin, and adrenomedullin 2000, 159-165. Landes Bioscience, Georgetown, Texas. D. Poyner, I. Marshall, S. Brain (Eds.).
    • (2000) The CGRP family: calcitonin gene-related peptide (CGRP), amylin, and adrenomedullin , pp. 159-165
    • Goadsby, P.J.1
  • 2
    • 78149272453 scopus 로고    scopus 로고
    • Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers
    • Asghar MS, Hansen AE, Kapijimpanga T, et al. Dilation by CGRP of middle meningeal artery and reversal by sumatriptan in normal volunteers. Neurology 2014, 75:1520-1526.
    • (2014) Neurology , vol.75 , pp. 1520-1526
    • Asghar, M.S.1    Hansen, A.E.2    Kapijimpanga, T.3
  • 3
    • 84882577435 scopus 로고    scopus 로고
    • CGRP receptor antagonism and migraine therapy
    • Edvinsson L, Warfvinge K CGRP receptor antagonism and migraine therapy. Curr Protein Pept Sci 2013, 14:386-392.
    • (2013) Curr Protein Pept Sci , vol.14 , pp. 386-392
    • Edvinsson, L.1    Warfvinge, K.2
  • 4
    • 1542346238 scopus 로고    scopus 로고
    • Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine
    • Olesen J, Diener HC, Husstedt IW, et al. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med 2004, 350:1104-1110.
    • (2004) N Engl J Med , vol.350 , pp. 1104-1110
    • Olesen, J.1    Diener, H.C.2    Husstedt, I.W.3
  • 5
    • 79953220801 scopus 로고    scopus 로고
    • BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study
    • Diener HC, Barbanti P, Dahlof C, Reuter U, Habeck J, Podhorna J BI 44370 TA, an oral CGRP antagonist for the treatment of acute migraine attacks: results from a phase II study. Cephalalgia 2010, 31:573-584.
    • (2010) Cephalalgia , vol.31 , pp. 573-584
    • Diener, H.C.1    Barbanti, P.2    Dahlof, C.3    Reuter, U.4    Habeck, J.5    Podhorna, J.6
  • 6
    • 79954607744 scopus 로고    scopus 로고
    • Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine
    • Hewitt DJ, Aurora SK, Dodick DW, et al. Randomized controlled trial of the CGRP receptor antagonist MK-3207 in the acute treatment of migraine. Cephalalgia 2011, 31:712-722.
    • (2011) Cephalalgia , vol.31 , pp. 712-722
    • Hewitt, D.J.1    Aurora, S.K.2    Dodick, D.W.3
  • 7
    • 84892162373 scopus 로고    scopus 로고
    • BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial
    • Marcus R, Goadsby PJ, Dodick D, Stock D, Manos G, Fischer TZ BMS-927711 for the acute treatment of migraine: a double-blind, randomized, placebo controlled, dose-ranging trial. Cephalalgia 2014, 34:114-125.
    • (2014) Cephalalgia , vol.34 , pp. 114-125
    • Marcus, R.1    Goadsby, P.J.2    Dodick, D.3    Stock, D.4    Manos, G.5    Fischer, T.Z.6
  • 8
    • 84906262129 scopus 로고    scopus 로고
    • Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
    • Dodick DW, Goadsby PJ, Spierings EL, Scherer JC, Sweeney SP, Grayzel DS Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study. Lancet Neurol 2014, 13:885-892.
    • (2014) Lancet Neurol , vol.13 , pp. 885-892
    • Dodick, D.W.1    Goadsby, P.J.2    Spierings, E.L.3    Scherer, J.C.4    Sweeney, S.P.5    Grayzel, D.S.6
  • 9
    • 84907964596 scopus 로고    scopus 로고
    • Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
    • published online Oct 6.
    • Dodick DW, Goadsby PJ, Silberstein SD, et al. Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial. Lancet Neurol 2014, for the ALD403 study investigators, published online Oct 6. http://dx.doi.org/10.1016/S1474-4422(14)70209-1.
    • (2014) Lancet Neurol
    • Dodick, D.W.1    Goadsby, P.J.2    Silberstein, S.D.3
  • 10
    • 84907987732 scopus 로고    scopus 로고
    • Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention
    • Ho TW, Connor KM, Zhang Y, et al. Randomized controlled trial of the CGRP receptor antagonist telcagepant for migraine prevention. Neurology 2014, 83:958-966.
    • (2014) Neurology , vol.83 , pp. 958-966
    • Ho, T.W.1    Connor, K.M.2    Zhang, Y.3
  • 11
    • 84865964987 scopus 로고    scopus 로고
    • Adherence with migraine prophylaxis in clinical practice
    • Berger A, Bloudek LM, Varon SF, Oster G Adherence with migraine prophylaxis in clinical practice. Pain Pract 2012, 12:541-549.
    • (2012) Pain Pract , vol.12 , pp. 541-549
    • Berger, A.1    Bloudek, L.M.2    Varon, S.F.3    Oster, G.4

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.